SOURCE: CLX Investment Company, Inc.

 

MURRIETA, CA--(Marketwire - March 25, 2008) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today released the March 2008 issue of its investor newsletter, which highlights the recent announcements regarding the company's preparations for planned clinical trials on Zonda's rapid point of care test for chlamydia. Clinical trials are being undertaken as part of the company's efforts to achieve FDA clearance for the chlamydia test and to begin distribution in the United States.

A PDF version of the March 2008 newsletter can be viewed on the company's corporate website at http://www.clxinvestments.com/newsletters.php.

The preparations for clinical trials that are highlighted in the newsletter include a feature article on the planned validation study for Zonda's chlamydia test, which is expected to perfect the testing protocol in preparation for the trials. The company is currently interviewing virology laboratories as candidates to conduct the study, which is anticipated to begin shortly.

In addition to the validation study, the newsletter reviews the recent engagement of Trial Care International to serve as Contract Research Organization (CRO) for the clinical trials. Trial Care International, LLC (http://trialcareintl.com) specializes in the management of Phase I-IV clinical trials in a wide range of therapeutic areas and provides clinical management, monitoring, auditing and regulatory services to the pharmaceutical and biotech industry.

Another newsletter article reviews the company's recent announcement that the tests that will be used in the trials have been placed in an FDA compliant, GMP approved secure storage facility provided by Sentry Logistic Solutions (http://www.sentrylogistic.com), a leading provider of temperature-controlled storage and third party logistics.

In her CEO Greeting, Vera Leonard comments, "The period since the publication of our last newsletter has been an eventful time for CLX, as we completed several very important steps in the process of preparing for clinical trials for Zonda's rapid point of care test for chlamydia."

She goes on to state, "In addition to this recent activity, we expect the next several weeks to hold even more significant announcements regarding the current activities and future direction of CLX, and we hope that shareholders continue to closely monitor our progress."

The newsletter also reviews the appointment of Pavel Holik to the position of director of commercial operations for Zonda. Mr. Holik has relocated to Zonda's new Dallas offices, which house the primary business operations, including the office of Ms. Leonard, who serves as president and chief executive officer of both Zonda and CLX Investment Company.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.